235 related articles for article (PubMed ID: 26327271)
1. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
[TBL] [Abstract][Full Text] [Related]
2. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
6. AIDS is your business.
Rosen S; Simon J; Vincent JR; MacLeod W; Fox M; Thea DM
Harv Bus Rev; 2003 Feb; 81(2):80-7, 125. PubMed ID: 12577655
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
9. HIV treatment and worker absenteeism: Quasi-experimental evidence from a large-scale health program in South Africa.
Jockers D; Langlotz S; French D; Bärnighausen T
J Health Econ; 2021 Sep; 79():102479. PubMed ID: 34438129
[TBL] [Abstract][Full Text] [Related]
10. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.
Granich R; Kahn JG; Bennett R; Holmes CB; Garg N; Serenata C; Sabin ML; Makhlouf-Obermeyer C; De Filippo Mack C; Williams P; Jones L; Smyth C; Kutch KA; Ying-Ru L; Vitoria M; Souteyrand Y; Crowley S; Korenromp EL; Williams BG
PLoS One; 2012; 7(2):e30216. PubMed ID: 22348000
[TBL] [Abstract][Full Text] [Related]
11. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
Ekpu VU; Brown AK
Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
[TBL] [Abstract][Full Text] [Related]
12. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
[TBL] [Abstract][Full Text] [Related]
13. The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research.
Rosen S; Feeley F; Connelly P; Simon J
AIDS; 2007 Jul; 21 Suppl 3():S41-51. PubMed ID: 17666961
[TBL] [Abstract][Full Text] [Related]
14. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
Binagwaho A; Pegurri E; Muita J; Bertozzi S
PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
[TBL] [Abstract][Full Text] [Related]
15. Cost implications of HIV retesting for verification in Africa.
Lasry A; Kalou MB; Young PR; Rurangirwa J; Parekh B; Behel S
PLoS One; 2019; 14(7):e0218936. PubMed ID: 31260467
[TBL] [Abstract][Full Text] [Related]
16. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study.
Rautenbach SP; Whittles LK; Meyer-Rath G; Jamieson L; Chidarikire T; Johnson LF; Imai-Eaton JW
Lancet Public Health; 2024 Apr; 9(4):e218-e230. PubMed ID: 38553141
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of HIV and antiretroviral therapy on education supply in high prevalence regions.
Risley CL; Drake LJ; Bundy DA
PLoS One; 2012; 7(11):e42909. PubMed ID: 23173030
[TBL] [Abstract][Full Text] [Related]
19. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
[TBL] [Abstract][Full Text] [Related]
20. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
Lo Sasso AT; Rost K; Beck A
Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
